ReviewClinical journal of gastroenterology2021
Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.
Review in Clinical journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.Frontiers in immunology · 2024Pooled it
- Safety and efficacy of robotic repeat hepatectomy compared to laparoscopic and open repeat hepatectomy: a retrospective comparative study.Updates in surgery · 2026Article
- Development and validation of a Random Forest prediction model integrating clinical and ultrasound radiomics features for microvascular invasion in hepatocellular carcinoma patients: a retrospective study.Translational cancer research · 2026Article
- A positive feedback loop between TKT and c-Myc drives TACE resistance in hepatocellular carcinoma.Cell death discovery · 2026Article
- Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.Cell reports. Medicine · 2026Article
- Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives.Cancers · 2026Review
- Non-Transplantable Recurrence After Initial Liver Resection of Hepatocellular Carcinoma: A Narrative Review.Cancers · 2026Review
- Article
- Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives.World journal of gastrointestinal oncology · 2025Review
- Transformer-Based Deep Learning for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma.Cancers · 2025Article
- Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).International journal of oncology · 2025Review
- Advancing microvascular invasion diagnosis: a multi-center investigation of novel MRI-based models for precise detection and classification in early-stage small hepatocellular carcinoma (≤ 3 cm).Abdominal radiology (New York) · 2025Article
- Article
- Intravoxel Incoherent Motion Improves the Accuracy of Preoperative Prediction of Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Adjuvant Sintilimab with or without Anti-VEGF Therapy After Resection in Hepatocellular Carcinoma with Microvascular Invasion: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Dual role of pyroptosis in liver diseases: mechanisms, implications, and therapeutic perspectives.Frontiers in cell and developmental biology · 2025Review
- Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance.Frontiers in oncology · 2025Review
- Surgical resection of late extrahepatic metastasis of hepatocellular carcinoma 11 years after initial diagnosis: case report and literature review.Journal of surgical case reports · 2024Article
- Clinical Nomogram Model for Pre-Operative Prediction of Microvascular Invasion of Hepatocellular Carcinoma before Hepatectomy.Medicina (Kaunas, Lithuania) · 2024Article
- Extracellular Vesicle-Related Non-Coding RNAs in Hepatocellular Carcinoma: An Overview.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma recurrence occurs in 40-70% of patients after hepatic resection. Despite the high frequency of hepatocellular cancer relapse, there is no established guidance for the management of such cases. The evaluation of prognostic factors that indicate a high risk of recurrence after surgery such as the tumor number and size and the presence of microvascular invasion may guide the therapeutic strategy and point out which patients should be strictly monitored. Additionally, the administration of adjuvant treatment or ab initio liver transplantation in selected patients with high-risk characteristics could have a significant impact on the prevention of relapse and overall survival. Once the recurrence has occurred in the liver remnant, the available therapeutic options include re-resection, salvage liver transplantation and locoregional treatments, although the therapeutic choice is often challenging and should be based on the characteristics of the recurrent tumor, the patient profile and most importantly the timing of relapse. Aggressive combination treatments are often required in challenging cases of early relapse. The results of the above treatment strategies are reviewed and compared to determine the optimal management of patients with recurrent hepatocellular cancer following liver resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.